Earnings
Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
Nuvig plans to use its funding to advance its lead molecule, complete some pre-IND enabling studies and move the molecule to the clinic to begin Phase I studies.
Despite posting its first profitable quarter as a commercial stage company, shares of Novavax plunged 20% in Tuesday trading due to the slower-than-expected rollout of its COVID-19 vaccine.
CRISPR Therapeutics reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
BioCryst’s success of its Orladeyo launch in its Q1 report was overshadowed by the news that the FDA had placed a partial clinical hold on three of its clinical trials evaluating BCX9930
Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.
Jazz’s Q1 included a key licensing deal with Werewolf Therapeutics and another announced Wednesday with Japan’s Sumitomo Pharma Co. for a narcolepsy treatment.
Despite the loss of its COVID-19 antibody, REGEN-COV, earlier this year, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.
PRESS RELEASES